cytotoxic T cell

(redirected from CD8 T-cells)
Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to CD8 T-cells: Killer T cells

cytotoxic T cell

cytotoxic T cell

See CD8 cell.

cytotoxic T cell

A CD8+ T lymphocyte that can destroy microorganisms directly through the release of perforin and proteolytic enzymes. These cells are particularly important in the defense against viruses, rejection of allografts, and, possibly, new malignant cells. Synonym: CD8 cell; cytotoxic cel; killer T cell
See also: cell
References in periodicals archive ?
They then took blood samples from HIV-infected individuals and separated out the CD8 T-cells and the CD4 T-cells - those infected with HIV.
Immuno-imaging of tumor-infiltrating CD8 T-cells with radiolabeled antibody fragments could provide a specific and sensitive modality to achieve this goal.
Data showed that Poly-ICR, in combination with model antigens, elicits strong anti-target antibody and CD8 T-cell immune responses.
Notably, using only half the vaccine dose, and only three doses as compared to four, CELLECTRA electroporation generated a 45% point increase (7% to 52%) in the generation of CD8 T-cells compared to the subjects that received a full dose without electroporation.
Three subjects from Cohort 3* have shown a doubling of their CD8 T-cells, with one subject displaying control of viral load below the LOQ during TI, and another displaying delayed onset of viremia during TI
Clinical trials conducted on more than 110 patients in Europe, North America and Taiwan have demonstrated the potential of IL-7 to expand and protect CD4 and CD8 T-cells.
It is also noteworthy that TAT0002 targets the uninfected CD8 T-cells, not the virus itself, so it should not be subject to resistance caused by mutational changes in HIV.
Cancer immunotherapy uses CD8 T-cells that have been engineered to express high avidity T-cell receptor (TCR) genes isolated from tumor-specific lymphocytes.
Our next-generation SynCon vaccines and CELLECTRA electroporation delivery devices have demonstrated best-in-class T-cell responses for HIV and cervical dysplasias caused by HPV and the ability to generate functional CD8 T-cells with antigen-specific killing activity in humans.
Furthermore, an indicator of underlying disease activity, the number of CD8 T-cells reactive to proinsulin, declined with TOL-3021 treatment, while T-cells against other antigens, such as infectious pathogens, were unaffected (p<0.